Zealand Pharma triples revenue
Zealand Pharma’s top line improved in 2023, while net operating costs decreased.
On the bottom line, there was still a large loss for the pharmaceutical group, which joined the C25 index at the end of December 2023.
Zealand Pharma had a turnover of DKK 342.8m (USD 49.9m) in 2023, up from DKK 104m (USD 15m) in 2022.
Net operating costs in the period totaled DKK 895.9m (USD 130m). This was as expected by the company, which had forecast net operating costs in the range of DKK 800-900m (USD 116-131m).
Zealand Pharma had costs of DKK 941.1m (USD 137m) in 2022.
On the bottom line, the company still reported a deficit in 2023. In total, Zealand Pharma had a loss of DKK 703.7m (USD 102m) after tax. This compares to a net loss of DKK 1202.1m (USD 174.9m) in 2022.
(Translated using DeepL with additional editing by Catherine Brett)
Related articles
Largest shareholder unloads Zealand Pharma shares
For subscribers
